A prospective study of plasma insulin-like growth factor-1 and binding protein-3 and risk of colorectal neoplasia in women

Cancer Epidemiology Biomarkers and Prevention

Volumn 9, Issue 4, 2000, Pages 345-349

  Giovannucci, Edward ^a,b,d   Pollak, Michael N ^c   Platz, Elizabeth A ^b   Willett, Walter C ^a,b   Stampfer, Meir J ^a,b   Majeed, Noreen ^c   Colditz, Graham A ^a   Speizer, Frank E ^a   Hankinson, Susan E ^a,b  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^c MCGILL UNIVERSITY   (Canada)

^d CHANNING LABORATORY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

SOMATOMEDIN BINDING PROTEIN 3; SOMATOMEDIN C;

ADULT; ARTICLE; BLOOD SAMPLING; CANCER GROWTH; CANCER RISK; CELL SURVIVAL; COLORECTAL CANCER; DRUG BLOOD LEVEL; DRUG EFFECT; FEMALE; HUMAN; MAJOR CLINICAL STUDY; PREMENOPAUSE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RECEPTOR UPREGULATION; TARGET CELL;

ADENOMA; AGED; COLORECTAL NEOPLASMS; FEMALE; HUMANS; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 3; INSULIN-LIKE GROWTH FACTOR I; MIDDLE AGED; PROGNOSIS; PROSPECTIVE STUDIES; RISK ASSESSMENT;

EID: 0034019059     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (48)

1. Aaronson, S. Growth factors and cancer. Science (Washington DC), 254: 1146-1153, 1991.
2. Jones, J., and Clemmons, D. Insulin-like growth factors and their binding proteins: biological actions. Endocr. Rev., 16: 3-34, 1995.
3. Rechler, M. Growth inhibition by insulin-like growth factor (IGF) binding protein-3 - what's IGF got to do with it? Endocrinology, 138: 2645-2647, 1997.
4. Rajah, R., Valentinis, B., and Cohen, P. Insulin-like growth factor (IGF)-binding protein-3 induces apoptosis and mediates the effects of transforming growth factor-β1 on programmed cell death through a p53 and IGF-independent mechanism. J. Biol. Chem., 272: 12181-12188, 1997.
5. Pollak, M., Costantino, J., Polychronakos, C., Blauer, S. A., Guyda, H., Redmond, C., Fisher, B., and Margolese, R. Effect of tamoxifen on serum insulin-like growth factor I levels in stage I breast cancer patients. J. Natl. Cancer. Inst., 82: 1693-1697, 1990.
6. Huynh, H., Yang, X., and Pollak, M. Estradiol and antiestrogens regulate a growth inhibitory insulin-like growth factor binding protein 3 autocrine loop in human breast cancer cells. J. Biol. Chem., 271: 1016-1021, 1996.
7. Pollak, M. N., Perdue, J. F., Margolese, R. G., Baer, K., and Richard, M. Presence of somatomedin receptors on primary human breast and colon carcinomas. Cancer Lett., 38: 223-230, 1987.
8. Guo, Y. S., Narayan, S., Yallampalli, C., and Singh, P. Characterization of insulin-like growth factor I receptors in human colon cancer. Gastroenterology, 102: 1101-1108, 1992.
9. Warren, R., Yuan, H., Matli, M., Ferrara, N., and Donner, D. Induction of vascular endothelial growth factor by insulin-like growth factor 1 in colorectal carcinoma. J. Biol. Chem., 271: 29483-29488, 1996.
10. Baserga, R. The insulin-like growth factor I receptor: a key to tumor growth? Cancer Res., 55: 249-252, 1995.
11. Cats, A., Dullaart, R., Kleibeuker, J., Kuipers, F., Sluiter, W., Hardonk, M., and de Vries, E. Increased epithelial cell proliferation in the colon of patients with acromegaly. Cancer Res., 56: 523-526, 1996.
12. Jenkins, P., Fairclough, P., Richards, T., Lowe, D., Monson, J., Grossman, A., Wass, J., and Besser, M. Acromegaly, colonic polyps and carcinoma. Clin. Endocrinol., 47: 17-22, 1997.
13. Chan, J. M., Stampfer, M. J., Giovannucci, E., Gann, P. H., Ma, J., Wilkinson, P., Hennekens, C. H., and Pollak, M. Plasma insulin-like growth factor-I and prostate cancer risk: a prospective study. Science (Washington DC), 279: 563-566, 1998.
14. Hankinson, S. E., Willett, W. C., Colditz, G. A., Hunter, D. J., Michaud, D. S., Deroo, B., Rosner, B., Speizer, F. E., and Pollak, M. Circulating concentrations of insulin-like growth factor-I and risk of breast cancer. Lancet, 351: 1393-1396, 1998.
15. Yu, H., Spitz, M. R., Mistry, J., Gu, J., Hong, W. K., and Wu, X. Plasma levels of insulin-like growth factor-I and lung cancer risk: a case-control analysis. J. Natl. Cancer Inst., 91: 151-156, 1999.
16. Ma, J., Pollak, M. N., Giovannucci, E., Chan, J. M., Tao, T., Hennekens, C. H., and Stampfer, M. J. Prospective study of colorectal cancer risk in men and plasma levels of insulin-like growth factor (IGF)-1 and IGF-binding protein-3. J. Natl. Cancer Inst., 91: 620-625, 1999.
17. Willett, W. C., Stampfer, M. J., Colditz, G. A., Rosner, B. A., Hennekens, C. H., and Speizer, F. E. Dietary fat and the risk of breast cancer. N. Engl. J. Med., 316: 22-28, 1987.
18. Willett, W. C., and Stampfer, M. J. Total energy intake: implications for epidemiologic analyses. Am. J. Epidemiol., 124: 17-27, 1986.
19. Potter, J. D., Slattery, M. L., Bostick, R. M., Gapstur, S. M. Colon cancer: a review of the epidemiology. Epidemiol. Rev., 15: 499-545, 1993.
20. Vogelstein, B., Fearon, E. R., Hamilton, S. R., Kern, S. E., Preisinger, A. C., Leppert, M., Nakamura, Y., White, R., Smits, A. M. M., and Bos, J. L. Genetic alterations during colorectal-tumor development. N. Engl. J. Med., 319: 525-532, 1988.
21. Goodman-Gruen, D., and Barrett-Connor, E. Epidemiology of insulin-like growth factor-I in elderly men and women: The Rancho Bernardo Study. Am. J. Epidemiol., 145: 970-976, 1997.
22. Giovannucci, E., Ascherio, A., Rimm, E. B., Colditz, G. A., Stampfer, M. J., and Willett, W. C. Physical activity, obesity, and risk for colon cancer and adenoma in men. Ann. Intern. Med., 122: 327-334, 1995.
23. Chute, C. G., Willett, W. C., Colditz, G. A., Stampfer, M. J., Baron, J. A., Rosner, B., and Speizer, F. E. A prospective study of body mass, height, and smoking on the risk of colorectal cancer in women. Cancer Causes Control, 2: 117-124, 1991.
24. Albanes, D., Jones, D. Y., Schatzkin, A., Micozzi, M. S., and Taylor, P. R. Adult stature and risk of cancer. Cancer Res., 48: 1658-1662, 1988.
25. Herbert, P. R., Ajani, U., Cook, N. R., Lee, I-M., Chan, K. S., and Hennekens, C. H. Adult height and incidence of cancer in male physicians (United States). Cancer Causes Control, 8: 591-597, 1997.
26. Juul, A., Bang, P., Hertel, N. T., Main, K., Dalgaard, P., Jorgensen, K., Muller, J., Hall, K., and Skakkebaek, N. E. Serum insulin-like growth factor-I in 1030 healthy children, adolescents, and adults: relation to age, sex, stage of puberty, testicular size, and body mass index. J. Clin. Endocrinol. Metab., 78: 744-752, 1994.
27. Giovannucci, E. Insulin and colon cancer. Cancer Causes Control, 6: 164-179, 1995.
28. Ooi, G. T., Tseng, L. Y., Tran, M. Q., and Rechler, M. M. Insulin rapidly decreases insulin-like growth factor binding protein-1 gene transcription in streptozotocin-diabetic rats. Mol. Endocrinol., 6: 2219-2228, 1992.
29. Powell, D. R., Suwanichkul, A., Cubbage, M. L., DePaolis, L. A., Snuggs, M. B., and Lee, P. D. Insulin inhibits transcription of the human gene for insulin-like growth factor-binding protein-1. J. Biol. Chem., 266: 18868-18876, 1991.
30. Katz, L. E. L., Cohen, P., and Rosenfeld, R. Clinical significance of IGF binding proteins. Endocrinologist, 5: 36-43, 1995.
31. Cohen, P., Fielder, P. J., Hasegawa, Y., Frisch, H., Giudice, L. C., and Rosenfeld, R. G. Clinical aspects of insulin-like growth factor binding proteins. Acta Endocrinol., 124: (Suppl. 2): 74-85, 1991.
32. Lee, P. D., Conover, C. A., and Powell, D. R. Regulation and function of insulin-like growth factor-binding protein-1. Proc. Soc. Exp. Biol. Med., 204: 4-29, 1993.
33. Cotterill, A. M., Holly, J. M., and Wass, J. A. The regulation of insulin-like growth factor binding protein (IGFBP)-1 during prolonged fasting. Clin. Endocrinol., 39: 357-362, 1993.
34. Busby, W. H., Snyder, D. K., and Clemmons, D. R. Radioimmunoassay of a 26,000-dalton plasma insulin-like growth factor-binding protein: control by nutritional variables. J. Clin. Endocrinol. Metab., 67: 1225-1230, 1988.
35. Suikkari, A. M., Sane, T., Seppala, M., Yki-Jarvinen, H., Karonen, S. L., and Koivisto, V. A. Prolonged exercise increases serum insulin-like growth factor-binding protein concentrations. J. Clin. Endocrinol. Metab., 68: 141-144, 1989.
36. Batch, J. A., Baxter, R. C., and Werther, G. Abnormal regulation of insulin-like growth factor binding proteins in adolescents with insulin-dependent diabetes. J. Clin. Endocrinol. Metab., 73: 964-968, 1991.
37. Brismar, K., Gutniak, M., Povoa, G., Werner, S., and Hall, K. Insulin regulates the 35 kDa IGF binding protein in patients with diabetes mellitus. J. Endocrinol. Investig., 11: 599-602, 1988.
38. Suikkari, A. M., Koivisto, V. A., Rutamen, E. M., Yki-Jarvinen, H., Karonen, S. L., and Seppala, M. Insulin regulates the serum levels of low molecular weight insulin-like growth factor-binding protein. J. Clin. Endocrinol. Metab., 66: 266-272, 1988.
39. Harrela, M., Koistinen, H., Kaprio, J., Lehtovirta, M., Tuomilehto, J., Eriksson, J., Toivanen, L., Koskenvuo, M., Leinonen, P., Koistinen, R., and Seppälä, M. Genetic and environmental components of interindividual variation in circulating levels of IGF-I, IGF-II, IGFBP-1, and IGFBP-3. J. Clin. Investig., 98: 2612-2615, 1996.
40. Isley, W. L., Underwood, L. E., and Clemmons, D. R. Dietary components that regulate serum somatomedin-C concentrations in humans. J. Clin. Investig., 71: 175-182, 1983.
41. Clemmons, D. R., Underwood, L. E., Dickerson, R. N., Brown, R. O., Hak, L. J., MacPhee, R. D., and Heizer, W. D. Use of plasma somatomedin-C/insulin-like growth factor I measurements to monitor the response to nutritional repletion in malnourished patients. Am. J. Clin. Nutr., 41: 191-198, 1985.
42. Unterman, T. G., Vazquez, R. M., Slas, A. J., Martyn, P. A., and Phillips, L. S. Nutrition and somatomedin. XIII. Usefulness of somatomedin-C in nutritional assessment. Am. J. Med., 78: 228-234, 1985.
43. Ruggeri, B. A., Klurfeld, D. M., Kritchevsky, D., and Furlanetto, R. W. Caloric restriction and 7,12-dimethylbenz(a)anthracene-induced mammary tumor growth in rats: alterations in circulating insulin, insulin-like growth factors I and II, and epidermal growth factor. Cancer Res., 49: 4130-4134, 1989.
44. Klurfeld, D. M., Lloyd, L. M., Welch, C. B., Davis, M. J., Tulp, O. L., and Kritchevsky, D. Reduction of enhanced mammary carcinogenesis in LA/N-cp (corpulent) rats by energy restriction. Proc. Soc. Exp. Biol. Med., 196: 381-384, 1991.
45. Pollak, M. N., Polychronakos, C., and Guyda, H. Somatostatin analogue SMS 201-995 reduces serum IGF-I levels in patients with neoplasms potentially dependent on IGF-I. Anticancer Res., 9: 889-891, 1989.
46. Zarandi, M., Horvath, J. E., Halmos, G., Pinski, J., Nagy, A., Groot, K., Rekasi, Z., and Schally, A. V. Synthesis and biological activities of highly potent antagonists of growth hormone-releasing hormone. Proc. Natl. Acad. Sci. USA, 91: 12298-12302, 1994.
47. Mantzoros, C. S., Tzonou, A., Signorello, L. B., Stampfer, M., Trichopoulos, D., and Adami, H-O. Insulin-like growth factor 1 in relation to prostate cancer and benign prostatic hyperplasia. Br. J. Cancer, 76: 1115-1118, 1997.
48. Rudman, D., Feller, A. G., Nagraj, H. S., Gergans, G. A., Lalitha, P. Y., Goldberg, A. F., Schlenker, R. A., Cohn, L., Rudman, I. W., and Mattson, D. E. Effects of human growth hormone in men over 60 years old. N. Engl. J. Med., 323: 1-6, 1990.